Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J Hedges On 2025 Pharma Revenue Outlook

Apr 18 2023

• By Jessica Merrill

missed target — J&J said it may miss a financial target it set for 2025 • Source: Shutterstock

Related Content

Janssen’s Spravato Enters US Market With Enhanced REMS And Plans For A Monotherapy Trial

Mar 07 2019

Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti

Mar 01 2022

J&J Lays Out ‘Responsibly Cautious’ Growth Outlook

Jan 24 2023

No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025

Nov 18 2021

With Stelara's Star Set To Fade, J&J Assures Investors It Will Grow Anyway

Oct 18 2022

Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake

Nov 24 2022

Related Companies

Johnson & Johnson

AstraZeneca PLC

Legend Biotech Corp.

Novartis AG

Additional Topics

Business Strategies Sales & Earnings Biosimilars Launches BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.